[go: up one dir, main page]

UY30937A1 - Disolucion solida amorfa que contiene un derivado de pirazol-3-carboxamida en forma amorfa y excipientes estabilizadores. - Google Patents

Disolucion solida amorfa que contiene un derivado de pirazol-3-carboxamida en forma amorfa y excipientes estabilizadores.

Info

Publication number
UY30937A1
UY30937A1 UY30937A UY30937A UY30937A1 UY 30937 A1 UY30937 A1 UY 30937A1 UY 30937 A UY30937 A UY 30937A UY 30937 A UY30937 A UY 30937A UY 30937 A1 UY30937 A1 UY 30937A1
Authority
UY
Uruguay
Prior art keywords
solid
carboxamide
derivative
amorphy
amorfa
Prior art date
Application number
UY30937A
Other languages
English (en)
Inventor
Bauer Michel
Menegotto Jerome
Alie Jean
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30937A1 publication Critical patent/UY30937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion se refiere a un derivado de pirazol-3-carboxamida en forma amorfa, a una disolucion solida amorfa que lo contiene y, más generalmente, a las composiciones farmacéuticas que lo contienen.
UY30937A 2007-02-23 2008-02-22 Disolucion solida amorfa que contiene un derivado de pirazol-3-carboxamida en forma amorfa y excipientes estabilizadores. UY30937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0701377A FR2913018A1 (fr) 2007-02-23 2007-02-23 Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs

Publications (1)

Publication Number Publication Date
UY30937A1 true UY30937A1 (es) 2008-09-30

Family

ID=38561793

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30937A UY30937A1 (es) 2007-02-23 2008-02-22 Disolucion solida amorfa que contiene un derivado de pirazol-3-carboxamida en forma amorfa y excipientes estabilizadores.

Country Status (20)

Country Link
US (1) US20100076023A1 (es)
EP (1) EP2132182A2 (es)
JP (1) JP2010519246A (es)
KR (1) KR20090113305A (es)
CN (1) CN101641333A (es)
AR (1) AR065410A1 (es)
AU (1) AU2008240507A1 (es)
BR (1) BRPI0807575A2 (es)
CA (1) CA2678801A1 (es)
CL (1) CL2008000550A1 (es)
CO (1) CO6210812A2 (es)
EA (1) EA200970792A1 (es)
FR (1) FR2913018A1 (es)
IL (1) IL200370A0 (es)
MA (1) MA31244B1 (es)
MX (1) MX2009008991A (es)
PE (1) PE20081778A1 (es)
TW (1) TW200846339A (es)
UY (1) UY30937A1 (es)
WO (1) WO2008129157A2 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
FR2873372B1 (fr) * 2004-07-22 2006-09-08 Sanofi Synthelabo Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
EP1844017A1 (en) * 2005-01-06 2007-10-17 Cadila Healthcare Ltd. An amorphous and three crystalline forms of rimonabant hydrochloride
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
WO2007103711A2 (en) * 2006-03-01 2007-09-13 Dr. Reddy's Laboratories Ltd. Polymorphic forms of rimonabant
WO2008102367A1 (en) * 2007-02-19 2008-08-28 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives

Also Published As

Publication number Publication date
AU2008240507A1 (en) 2008-10-30
TW200846339A (en) 2008-12-01
MA31244B1 (fr) 2010-03-01
CL2008000550A1 (es) 2008-07-04
CO6210812A2 (es) 2010-10-20
CN101641333A (zh) 2010-02-03
AR065410A1 (es) 2009-06-03
BRPI0807575A2 (pt) 2014-07-01
PE20081778A1 (es) 2009-01-01
WO2008129157A4 (fr) 2009-03-05
WO2008129157A2 (fr) 2008-10-30
IL200370A0 (en) 2010-04-29
WO2008129157A3 (fr) 2008-12-31
MX2009008991A (es) 2009-09-03
EA200970792A1 (ru) 2010-04-30
KR20090113305A (ko) 2009-10-29
FR2913018A1 (fr) 2008-08-29
EP2132182A2 (fr) 2009-12-16
CA2678801A1 (fr) 2008-10-30
US20100076023A1 (en) 2010-03-25
JP2010519246A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
CR11267A (es) Preparacion solida que contiene alogliptina y clorhidrato de metformina
CR10027A (es) Nuevos derivados de pirrol fusionado
DK2068822T3 (da) Selvpræserverede vandige farmaceutiske sammensætninger
EP2285411A4 (en) NICOTINE COMPOSITION IN THE FORM OF AIRBOX
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
HN2011003371A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CR11078A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
PA8846401A1 (es) Sinergismo antibiótico
AR077915A1 (es) Forma cristalina de pemirolast
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130205